Tanzania Sickle Cell Programme (360G-Wellcome-095009_Z_10_Z)
Over the last four years the Muhimbili Sickle Cohort (MSC) of patients with Sickle Cell Anaemia (SCA) has more than doubled from about 1800 in 2011 to over 4000 in 2015. Much of the Strategic Award has been spent on supporting the cohort, supporting Master students and one PhD student. In addition the Strategic Award has supported other studies which were not fully funded e.g. ethical studies and contributed to other studies, e.g. genetic studies, by providing laboratory support. A clinical problem encountered frequently is that haemoglobins are lower than those recorded in Western patients with SCA. One explanation is the reduced blood transfusions in Africa, given the lack of blood and concerns about the safety of blood transfusion. However iron deficiency in much more common in Africa, and iron deficiency anaemia may reduce the haemoglobin in patients with SCA living in Africa. We have shown that iron deficiency is associated with poor cardiac function in non-SCA, and this may aggravate the poor cardiac function that we have documented in Tanzanian patients with SCA. Iron supplementation in older children and adults improves attention and concentration irrespective of baseline iron status, and in those with anaemia, supplementation improved intelligent quotient on formal testing. The diagnosis of iron deficiency is problematic in SCA, particular in Africa where the high prevalence of alpha thalassaemia, high erythropoietic rate and chronic inflammation influence the parameters used to measure body iron stores. In many cases the only way to determine if the patient is iron deficient is to give a trial of iron therapy and monitor the response. However this strategy is confounded by the lack of reliable markers of adherence to the iron therapy. We are applying for funds to identify the most reliable markers of iron in the blood compared to iron measured in tissues in particular liver, brain and heart, with non-invasive magnetic resonance imaging (MRI), and assess the effect of low iron and iron supplementation on the function of these organs with biochemical, physiological and imaging techniques. These studies will be used to develop an application for a larger study examining iron deficiency and overload in Tanzanian patients with SCA.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Region | International |
| Award Date | 2009-12-14T00:00:00+00:00 |
| Internal ID | 095009/Z/10/Z |
| Planned Dates: End Date | 2016-09-30T00:00:00+00:00 |
| Planned Dates: Start Date | 2011-04-01T00:00:00+00:00 |
| Amount Awarded | 797093 |
| Financial Year | 2009/10 |
| Lead Applicant | Prof Charles Newton |
| Grant Programme: Title | Strategic Award - Science |
| Applicant Surname | Newton |
| Approval Committee | Strategic Awards Committee |
| Recipient Org: Country | Tanzania |
| Recipient Org: City | Upanga, Dar es Salaam |
| Has the grant transferred? | No |
| Research conducted at multiple locations? | No |
| Total amount including partnership funding | 797093 |